Analyst Price Target is $9.33
▲ +652.69% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Passage Bio in the last 3 months. The average price target is $9.33, with a high forecast of $14.00 and a low forecast of $5.00. The average price target represents a 652.69% upside from the last price of $1.24.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Passage Bio. This Buy consensus rating has held steady for over two years.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More